BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12176616)

  • 1. Induction therapy for adult small bowel transplant with Campath-1H.
    Nishida S; Levi D; Kato T; Madariaga J; Nery J; Tzakis A
    Transplant Proc; 2002 Aug; 34(5):1889-91. PubMed ID: 12176616
    [No Abstract]   [Full Text] [Related]  

  • 2. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD
    Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Campath-1H in intestinal and multivisceral transplantation: preliminary data.
    Tzakis AG; Kato T; Nishida S; Levi D; Madariaga J; De Faria W; Nery J; Neff G; Kirk AD; Ruiz P
    Transplant Proc; 2002 May; 34(3):937. PubMed ID: 12034248
    [No Abstract]   [Full Text] [Related]  

  • 4. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M; Weppler D; Mittal N; Nishida S; Kato T; Tzakis A; Ruiz P
    Transplant Proc; 2004 Mar; 36(2):323-4. PubMed ID: 15050146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
    Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
    Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients.
    Nishida S; Levi DM; Moon JI; Madariaga JR; Kato T; Selvaggi G; Tryphonopoulos P; DeFaria W; Santiago S; Gaynor J; Weppler D; Martinez E; Ruiz P; Tzakis AG
    Transplant Proc; 2006; 38(6):1747-9. PubMed ID: 16908270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
    Woodside KJ; Lick SD
    J Heart Lung Transplant; 2007 Jul; 26(7):750-2. PubMed ID: 17613409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Campath-1H use in pediatric renal transplantation.
    Bartosh SM; Knechtle SJ; Sollinger HW
    Am J Transplant; 2005 Jun; 5(6):1569-73. PubMed ID: 15888071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use.
    Das B; Shoemaker L; Recto M; Austin E; Dowling R
    J Heart Lung Transplant; 2008 Feb; 27(2):242-4. PubMed ID: 18267235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
    Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
    Reams BD; Davis RD; Curl J; Palmer SM
    Transplantation; 2002 Sep; 74(6):903-4. PubMed ID: 12364881
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction therapy for clinical intestinal transplantation: comparison of four different regimens.
    Pinna AD; Weppler D; Nery JR; Khan F; Ruiz P; Kato T; De Faria W; Berho M; Tzakis AG
    Transplant Proc; 2000 Sep; 32(6):1193-4. PubMed ID: 10995902
    [No Abstract]   [Full Text] [Related]  

  • 17. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
    Clatworthy MR; Friend PJ; Calne RY; Rebello PR; Hale G; Waldmann H; Watson CJ
    Transplantation; 2009 Apr; 87(7):1092-5. PubMed ID: 19352132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Campath 1H induction in adult liver allotransplantation.
    Tryphonopoulos P; Madariaga JR; Kato T; Nishida S; Levi DM; Moon J; Selvaggi G; De Faria W; Regev A; Bejarano P; Khaled A; Safdar K; Esquenazi V; Weppler D; Yoshida H; Ruiz P; Miller J; Tzakis AG
    Transplant Proc; 2005 Mar; 37(2):1203-4. PubMed ID: 15848669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.